Unlocking The Potential of PAFAH1B2 as A Drug Target and Biomarker

Target Name: PAFAH1B2

NCBI ID: G5049

PAFAH1B2

Other Name(s): Platelet-activating factor acetylhydrolase IB subunit alpha2 (isoform a) | platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (30kDa) | PAF acetylhydrolase 30 kDa subunit | PAF-AH subunit beta | Platelet activating factor acetylhydrolase 1b catalytic subunit 2, transcript variant 1 | platelet activating factor acetylhydrolase 1b catalytic subunit 2 | PAFAH1B2 variant 2 | epididymis secretory sperm binding protein | PAFAH1B2 variant 1 | PA1B2_HUMAN | intracellular platelet-activating factor acetylhydrolase alpha 2 subunit | Platelet-activating factor acetylhydrolase, isoform Ib, subunit 2 (30kDa) | Platelet-activating factor acetylhydrolase IB subunit beta | Intracellular platelet-activating factor acetylhydrolase alpha 2 subunit | PAFAH subunit beta | epididymis secretory protein Li 303 | HEL-S-303 | Platelet-activating factor acetylhydrolase IB subunit alpha2 (isoform b) | platelet-activating factor acetylhydrolase IB subunit beta | Platelet-Activating Factor Acetylhydrolase IB Subunit Beta | PAF-AH 30 kDa subunit | Platelet activating factor acetylhydrolase 1b catalytic subunit 2, transcript variant 2 | Platelet-activating factor acetylhydrolase IB subunit alpha2 | Epididymis secretory protein Li 303 | PAF-AH1b alpha 2 subunit | PAFAHB

Unlocking The Potential of PAFAH1B2 as A Drug Target and Biomarker

Unlocking the Potential of Platelet-Activating Factor Acetylhydrolase IB Subunit Alpha-2 (PAFAH1B2) as a Drug Target and Biomarker

Platelet-activating factor acetylhydrolase IB subunit alpha2 (PAFAH1B2) is a protein that plays a critical role in the regulation of platelet function and blood clotting. The encoded protein is a key component of platelet aggregation and helps maintain the integrity of platelet aggregates. The protein has been identified as a potential drug target and biomarker for various cardiovascular diseases, including thrombosis, ischemia, and hypertension.

PAFAH1B2: Structure and Function

The PAFAH1B2 protein is a member of the A-尾-hydrolase family and is expressed in various tissues, including platelets, endothelial cells, and smooth muscle cells. The protein has a molecular weight of approximately 120 kDa and consists of 118 amino acid residues. It has a distinct N-terminus, a catalytic center, and a C-terminus that is involved in its interactions with other proteins.

PAFAH1B2 functions as a negative regulator of platelet aggregation. It is involved in the regulation of platelet activation, aggregation, and disintegration. The protein has been shown to inhibit platelet aggregation in various models, including in vitro and in vivo systems.

Drug Target Potential

PAFAH1B2 has been identified as a potential drug target due to its critical role in the regulation of platelet function. The protein has been shown to be involved in various signaling pathways, including the TGF-β pathway, which plays a crucial role in the regulation of cell proliferation and survival.

In addition to its role in platelet function, PAFAH1B2 has also been shown to be involved in the regulation of angiogenesis, fibrosis, and inflammation. Its expression has been observed in various types of cancer, including breast, colon, and skin cancers.

PAFAH1B2 has also been shown to be a potential biomarker for various cardiovascular diseases, including thrombosis, ischemia, and hypertension. The protein has been shown to be involved in the regulation of platelet function in these diseases and has been used as a diagnostic marker for platelet function disorders.

Biomarker Potential

PAFAH1B2 has been shown to be involved in various signaling pathways that are involved in the regulation of cardiovascular disease. Its expression has been observed in various cardiovascular diseases, including heart failure, hypertension, and thrombosis.

PAFAH1B2 has also been shown to be involved in the regulation of angiogenesis and fibrosis. Its expression has been observed in various types of cancer, including breast, colon, and skin cancers. The protein has been shown to play a role in the regulation of cell proliferation and survival, as well as the formation of new blood vessels.

Conclusion

PAFAH1B2 is a protein that has been identified as a potential drug target and biomarker for various cardiovascular diseases. Its role in the regulation of platelet function and blood clotting makes it an attractive target for the development of new therapies for thrombosis, ischemia, and hypertension. The protein has also been shown to be involved in the regulation of angiogenesis, fibrosis, and inflammation, making it a potential target for the development of new therapies for various types of cancer. Further research is needed to fully understand the role of PAFAH1B2 as a drug target and biomarker for cardiovascular disease.

Protein Name: Platelet Activating Factor Acetylhydrolase 1b Catalytic Subunit 2

Functions: Alpha2 catalytic subunit of the cytosolic type I platelet-activating factor (PAF) acetylhydrolase (PAF-AH (I)) heterotetrameric enzyme that catalyzes the hydrolyze of the acetyl group at the sn-2 position of PAF and its analogs and modulates the action of PAF. The activity and substrate specificity of PAF-AH (I) are affected by its subunit composition. The alpha2/alpha2 homodimer (PAFAH1B2/PAFAH1B2 homodimer) hydrolyzes PAF and 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylethanolamine (AAGPE) more efficiently than 1-O-alkyl-2-acetyl-sn-glycero-3-phosphoric acid (AAGPA). In contrast, the alpha1/alpha2 heterodimer(PAFAH1B3/PAFAH1B3 heterodimer) hydrolyzes AAGPA more efficiently than PAF, but has little hydrolytic activity towards AAGPE (By similarity). May play a role in male germ cell meiosis during the late pachytenestage and meiotic divisions as well as early spermiogenesis (By similarity)

The "PAFAH1B2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAFAH1B2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets